Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke

Content Provider	Scilit
Author	Switzer, Jeffrey A. Hess, David C. Ergul, Adviye Waller, Jennifer L. Machado, Sandro Portik-Dobos, Vera Pettigrew, Luther Creed Clark, Wayne M. Fagan, Susan C.
Copyright Year	2011
Description	Journal: Stroke Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P =0.0022; non-tPA, P =0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P <0.0001; non-tPA, P =0.0019). Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.
Related Links	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181080/pdf https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.111.618215
Ending Page	2635
Page Count	3
Starting Page	2633
ISSN	00392499
e-ISSN	15244628
DOI	10.1161/strokeaha.111.618215
Journal	Stroke
Issue Number	9
Volume Number	42
Language	English
Publisher	Ovid Technologies (Wolters Kluwer Health)
Publisher Date	2011-09-01
Access Restriction	Open
Content Type	Text
Resource Type	Article
Subject	Cardiology and Cardiovascular Medicine Neuroscience Advanced and Specialized Nursing Neurology (clinical)